Conservative Physicians Accuse Medical Boards of Censorship

Why It Matters

A ruling could redefine the limits of private medical boards’ power over physicians’ speech and market access, potentially reshaping credentialing standards across the U.S. healthcare system.

Key Takeaways

• ABIM removed board certifications of Kory and Marik for ivermectin advocacy
• Plaintiffs claim certification threats violate First Amendment and antitrust law
• Courts view board certification as quasi‑state function affecting employment and reimbursement
• Outcome may force medical boards to revise disciplinary standards for political speech

Pulse Analysis

Board certification has long been a cornerstone of professional credibility in U.S. medicine, signaling that a physician meets rigorous educational and ethical standards. In recent years, the process has become a flashpoint as specialty boards like ABIM and ABOG have taken disciplinary actions against doctors whose public statements diverge from mainstream consensus. The most visible example involves Drs. Pierre Kory and Paul Marik, whose advocacy for ivermectin as a Covid‑19 treatment led ABIM to revoke their certifications, sparking accusations that the boards are policing ideology as much as competence.

The plaintiffs’ lawsuit hinges on two legal theories: that the boards’ actions constitute government‑like regulation infringing on First Amendment free‑speech rights, and that their monopoly over certification creates antitrust concerns. Lower courts dismissed the case, citing the boards’ status as private entities not subject to state‑actor analysis. However, the Fifth Circuit’s willingness to revisit the claims underscores a growing judicial interest in how private standards intersect with public policy, especially when they effectively control market entry for physicians. The argument that decertification can end a medical career by influencing hospital hiring and insurer reimbursement adds weight to the antitrust angle.

If the appellate court sides with the physicians, the decision could force specialty boards to adopt more narrowly defined disciplinary criteria, limiting punitive measures to clear violations of clinical competence rather than controversial viewpoints. Such a shift would reverberate through hospitals, insurance networks, and academic institutions that rely on board status for credentialing and reimbursement decisions. Moreover, the case signals a broader trend of politicization in professional regulation, prompting other industries to reassess how private certification bodies balance expertise with ideological neutrality.